
speaker
Vance Fowler
MD, MHS
Medicine
Infectious Disease, Internal Medicine
Durham, North Carolina, United States
Professor
He is a co-founder of the International Collaboration on Endocarditis (ICE) and published the critical observation that S. aureus is now the leading cause of endocarditis in the industrialized world. He was the lead author on the Phase III trial that led to the FDA indication of daptomycin for SAB (Fowler NEJM, 2006), on the multinational trial of Merck V710 vaccine for S. aureus (Fowler JAMA 2013), and the Phase II trial of Bacteriophage-derived lysins for S. aureus bacteremia (Fowler J Clin Invest 2020).
He was the senior author on 2 Phase II trials of immunotherapeutic treatments of SAB, a randomized trial on staphylococcal bacteremia (Holland JAMA, 2018), and the recently completed Phase III of ceftobiprole for S. aureus bacteremia (Holland, NEJM, 2023). He has led multiple clinical studies involving the Karius test in S. aureus bacteremia (Eichenberger, Clin Infect Dis 2022) and endocarditis (Eichenberger, Clin Infect Dis, 2023). He received the Clinical Research Achievement Award for publishing one of the top ten clinical research papers in the US in 2012, and the Translational Research Mentoring Award from Duke University School of Medicine in 2018. He has over 350 peer-reviewed publications, over 33,000 citations, and a Web of Science h-index of 89.